Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - A prospective study

M. Khadadah, B. Jayakrishnan, S. Al-Gorair, M. Al-Mutairi, N. Al-Maradni, B. Onadeko, A. Malaviya

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

If given in high doses, methotrexate (MTX), a folate antagonist, could cause pulmonary complications. To evaluate the pulmonary effects of low-dose methotrexate, 55 newly diagnosed patients with rheumatoid arthritis (RA) prescribed with MTX were studied prospectively. A significant reduction in percent predicted values of forced expiratory volume (FEV1), forced vital capacity (FVC), total lung capacity (TLC), and functional residual capacity (FRC) was observed after 2 years of MTX treatment. A significant increase in the FEV1:FVC ratio was also observed. In comparison to the normal annual decline in healthy adults, the actual reduction in observed values in the patients was significantly greater (3.2, 6.3, and 6.7 times normal for FEV1, FVC, and TLC, respectively). PaO2 and oxygen saturation showed marginal but significant improvement. It was concluded that low-dose MTX treatment in RA might cause an accelerated decline in lung function. Therefore, periodic monitoring of pulmonary function among RA patients started on MTX could be necessary.

Original languageEnglish
Pages (from-to)204-207
Number of pages4
JournalRheumatology International
Volume22
Issue number5
DOIs
Publication statusPublished - 2002

Fingerprint

Methotrexate
Rheumatoid Arthritis
Prospective Studies
Lung
Vital Capacity
Total Lung Capacity
Functional Residual Capacity
Forced Expiratory Volume
Folic Acid
Oxygen
Therapeutics

Keywords

  • Methotrexate
  • Pulmonary function test
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - A prospective study. / Khadadah, M.; Jayakrishnan, B.; Al-Gorair, S.; Al-Mutairi, M.; Al-Maradni, N.; Onadeko, B.; Malaviya, A.

In: Rheumatology International, Vol. 22, No. 5, 2002, p. 204-207.

Research output: Contribution to journalArticle

Khadadah, M. ; Jayakrishnan, B. ; Al-Gorair, S. ; Al-Mutairi, M. ; Al-Maradni, N. ; Onadeko, B. ; Malaviya, A. / Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - A prospective study. In: Rheumatology International. 2002 ; Vol. 22, No. 5. pp. 204-207.
@article{476527dc0b764335825c4e0d66a8ea7a,
title = "Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - A prospective study",
abstract = "If given in high doses, methotrexate (MTX), a folate antagonist, could cause pulmonary complications. To evaluate the pulmonary effects of low-dose methotrexate, 55 newly diagnosed patients with rheumatoid arthritis (RA) prescribed with MTX were studied prospectively. A significant reduction in percent predicted values of forced expiratory volume (FEV1), forced vital capacity (FVC), total lung capacity (TLC), and functional residual capacity (FRC) was observed after 2 years of MTX treatment. A significant increase in the FEV1:FVC ratio was also observed. In comparison to the normal annual decline in healthy adults, the actual reduction in observed values in the patients was significantly greater (3.2, 6.3, and 6.7 times normal for FEV1, FVC, and TLC, respectively). PaO2 and oxygen saturation showed marginal but significant improvement. It was concluded that low-dose MTX treatment in RA might cause an accelerated decline in lung function. Therefore, periodic monitoring of pulmonary function among RA patients started on MTX could be necessary.",
keywords = "Methotrexate, Pulmonary function test, Rheumatoid arthritis",
author = "M. Khadadah and B. Jayakrishnan and S. Al-Gorair and M. Al-Mutairi and N. Al-Maradni and B. Onadeko and A. Malaviya",
year = "2002",
doi = "10.1007/s00296-002-0227-6",
language = "English",
volume = "22",
pages = "204--207",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - A prospective study

AU - Khadadah, M.

AU - Jayakrishnan, B.

AU - Al-Gorair, S.

AU - Al-Mutairi, M.

AU - Al-Maradni, N.

AU - Onadeko, B.

AU - Malaviya, A.

PY - 2002

Y1 - 2002

N2 - If given in high doses, methotrexate (MTX), a folate antagonist, could cause pulmonary complications. To evaluate the pulmonary effects of low-dose methotrexate, 55 newly diagnosed patients with rheumatoid arthritis (RA) prescribed with MTX were studied prospectively. A significant reduction in percent predicted values of forced expiratory volume (FEV1), forced vital capacity (FVC), total lung capacity (TLC), and functional residual capacity (FRC) was observed after 2 years of MTX treatment. A significant increase in the FEV1:FVC ratio was also observed. In comparison to the normal annual decline in healthy adults, the actual reduction in observed values in the patients was significantly greater (3.2, 6.3, and 6.7 times normal for FEV1, FVC, and TLC, respectively). PaO2 and oxygen saturation showed marginal but significant improvement. It was concluded that low-dose MTX treatment in RA might cause an accelerated decline in lung function. Therefore, periodic monitoring of pulmonary function among RA patients started on MTX could be necessary.

AB - If given in high doses, methotrexate (MTX), a folate antagonist, could cause pulmonary complications. To evaluate the pulmonary effects of low-dose methotrexate, 55 newly diagnosed patients with rheumatoid arthritis (RA) prescribed with MTX were studied prospectively. A significant reduction in percent predicted values of forced expiratory volume (FEV1), forced vital capacity (FVC), total lung capacity (TLC), and functional residual capacity (FRC) was observed after 2 years of MTX treatment. A significant increase in the FEV1:FVC ratio was also observed. In comparison to the normal annual decline in healthy adults, the actual reduction in observed values in the patients was significantly greater (3.2, 6.3, and 6.7 times normal for FEV1, FVC, and TLC, respectively). PaO2 and oxygen saturation showed marginal but significant improvement. It was concluded that low-dose MTX treatment in RA might cause an accelerated decline in lung function. Therefore, periodic monitoring of pulmonary function among RA patients started on MTX could be necessary.

KW - Methotrexate

KW - Pulmonary function test

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0036039382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036039382&partnerID=8YFLogxK

U2 - 10.1007/s00296-002-0227-6

DO - 10.1007/s00296-002-0227-6

M3 - Article

VL - 22

SP - 204

EP - 207

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 5

ER -